Pembrolizumab plus enfortumab vedotin in urothelial cancer

Abstract

The combination of pembrolizumab and enfortumab vedotin shows promise as a first-line therapy for advanced urothelial carcinoma. Enfortumab vedotin targets nectin-4, in turn enhancing T cell and natural killer cell activity, inhibiting immunosuppressive pathways and impeding tumour evasion.

This synergy with pembrolizumab shows potential in enhancing immunotherapy for these patients.

Keywords

• Pembrolizumab
• enfortumab
• vedotin
• urothelial
• cancer